Regarding DNMT inhibitors, two phase 1 disease-specific studies investigating the combination of azacytidine with cisplatin were terminated due to accrual issues, thus still leaving the question open as to whether azacytidine may potentiate the effect of platinum-based chemotherapy in R/M HNSCC. Here, DNMT1 is linked to head and neck squamous cell carcinoma.